Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
* Correspondence: Tiffany M
The limited treatment landscape has created significant interest in repurposing existing drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, which address multiple metabolic pathways implicated in fatty liver disease
Under normal physiological conditions, the synthesis and degradation of free fatty acids, triglycerides and total cholesterol in the body are in a dynamic equilibrium (15)
An investigational lab-made peptide (research code LY3437943) from Eli Lilly, now in Phase 3 trials
US$ 29.51
US$ 20.01
US$ 29.42
US$ 22.61
US$ 29.45
US$ 26.74
US$ 24.23
US$ 21.50
